Transforming Lives

Through a new class of safe, durable cancer treatments.

Our Team

Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.
Learn more
Our Science

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.
Learn more
Alliances

Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.
Learn more

Learn More About ONC201 Clinical Trials

In The News

- AUG 03 2017
Manuscript on ONC201’s Effect on Cancer Stem Cells Published in PLOS ONE
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression Pre-treatment gene expression of cancer stem cells may help predict response to ONC201 ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from

Read >

- JUL 14 2017
Musella Foundation Awards Oncoceutics New Research Grant
The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma

Read >

Press Releases

May 29 2018
Oncoceutics Abstracts at ASCO Highlight Efficacy of ONC201 in High-Grade Gliomas

Read >

Events

Sep 06 2015
Oncoceutics to Present at the BIO Investor Forum

Read >
May 30 2015
First-in-Man ONC201 Trial to be Presented at 2015 ASCO Meeting

Read >
May 30 2015
ASCO Annual Meeting 2015

Read >
May 29 2015
Brain Tumor Biotech Summit 2015

Read >